Posterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma
Background. The role of immunotherapy continues to evolve across both solid and hematologic malignancies. However, while use of immunotherapy has increased via the advent of checkpoint inhibition, chimeric antigen receptors, and vaccines against malignant cells, there remains uncertainty regarding t...
Main Authors: | J. M. Sabile, D. J. Grider, K. A. Prickett, H. Li, P. V. Mallidi |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2021/8845063 |
Similar Items
-
Daptomycin-Induced Posterior Reversible Encephalopathy Syndrome (PRES)
by: A. Bitar De Zayas-Enriquez, et al.
Published: (2019-01-01) -
Posterior Reversible Encephalopathy Syndrome (PRES) in the peripartum period
by: Jayati Nath
Published: (2018-07-01) -
Posterior Reversible Encephalopathy Syndrome (PRES): Pathophysiology and Neuro-Imaging
by: Redmond-Craig Anderson, et al.
Published: (2020-06-01) -
Posterior Reversible Encephalopathy Syndrome (Pres) – A Case Report
by: Melis Türker, et al.
Published: (2011-12-01) -
Posterior Reversible Encephalopathy Syndrome (PRES) in Rheumatic Autoimmune Disease
by: Izzat Khanjar, et al.
Published: (2018-03-01)